FDA approves primary biliary cholangitis drug
The Saudi Food and Drug Authority has approved the registration of the product "Aykirfo" for the treatment of primary biliary cirrhosis in adults who do not respond to previous treatments. The product is used to improve bile flow and reduce liver fibrosis. Studies have shown that it results in improved enzyme levels and alleviates common side effects such as abdominal pain and headaches.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)